Want to see IRIX full AI Analyst Report?
IRIX Stock Chart & Stats
$0.89
>-$0.01(-0.56%)
At close: 4:00 PM EDT
$0.89
>-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$0.80 - $1.65
Previous CloseN/A
Volume11.00K
Average Volume (3M)66.91K
Market Cap
$14.27M
Enterprise Value$22.65
Total Cash (Recent Filing)$4.59M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 06, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding17,406,519
10 Day Avg. Volume69,445
30 Day Avg. Volume66,914
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.09
Price to Sales (P/S)0.38
P/FCF Ratio-8.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.75Price Target Upside208.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$53.00M
Bulls Say, Bears Say
Bulls Say
Installed-base Recurring ConsumablesIridex’s business model includes recurring sales of single‑use probes and procedure consumables tied to an installed base. That creates durable, higher‑frequency demand and revenue visibility, smoothing capital equipment cyclicality and supporting margin recovery and cash flow over coming quarters.
Product-level Demand MomentumRising unit sales for G‑Probes and Cyclo G6 revenue growth indicate sustained clinical adoption and pricing power at the product level. Durable adoption of core consumables and therapy platforms supports recurring revenue, installed‑base expansion and cross‑sell opportunities over multiple quarters.
Cost And Manufacturing InitiativesTargeted G&A relocation savings and a multi‑year shift to contract manufacturing materially improve operating leverage and prospective gross margins. These structural cost reductions increase the likelihood of sustainable positive operating cash flow and higher profitability as transitions complete.
Bears Say
Revenue Decline And Margin CompressionAn 18% TTM revenue decline and materially compressed gross margins reflect weaker top‑line dynamics and cost pressures (tariffs, mix). Persistent revenue contraction and lower gross profit margins limit scalable operating leverage and make sustained profitability harder without structural mix or pricing improvements.
Cash Burn And Thin Capital BaseNegative operating and free cash flow alongside a modest cash balance and thin equity leave limited cushion for execution risk. Over the next several quarters the company faces funding risk for product shipments, regulatory delays, or working‑capital needs absent materially improved cash generation or external financing.
Governance And Control UncertaintyAn active investigation and a large strategic investor with contested actions create persistent governance uncertainty. Potential proxy battles, dilution proposals or litigation can distract management, delay strategic initiatives and complicate capital‑raising or partner negotiations for multiple months.
Iridex News
IRIX FAQ
What was Iridex Corp’s price range in the past 12 months?
Iridex Corp lowest stock price was $0.80 and its highest was $1.65 in the past 12 months.
What is Iridex Corp’s market cap?
Iridex Corp’s market cap is $14.27M.
When is Iridex Corp’s upcoming earnings report date?
Iridex Corp’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Iridex Corp’s earnings last quarter?
Iridex Corp released its earnings results on May 19, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.04.
Is Iridex Corp overvalued?
According to Wall Street analysts Iridex Corp’s price is currently Undervalued.
Does Iridex Corp pay dividends?
Iridex Corp does not currently pay dividends.
What is Iridex Corp’s EPS estimate?
Iridex Corp’s EPS estimate is -0.01.
How many shares outstanding does Iridex Corp have?
Iridex Corp has 17,406,519 shares outstanding.
What happened to Iridex Corp’s price movement after its last earnings report?
Iridex Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Iridex Corp?
Currently, no hedge funds are holding shares in IRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iridex Corp
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
IRIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: solid operational progress (probe and Cyclo G6 growth, cost reductions, partnership expansion, and a near‑term $0.8M backlog) balanced against notable international headwinds, a YoY gross margin decline, softer retina system sell‑through, and a quarter‑end cash decline. Management reaffirmed full‑year guidance ($51M–$53M excluding the Middle East), expects full‑year positive operating cash flow, and highlighted multi‑quarter initiatives (G&A relocation and contract manufacturer transition) that should improve margins over time. Near‑term risks are primarily timing and international/regulatory disruptions rather than fundamental demand weakness in core U.S. businesses.View all IRIX earnings summariesIRIX Stock 12 Month Forecast
Average Price Target
$2.75
▲(208.99% Upside)
Technical Analysis
Sintx Technologies
―
PAVmed
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Envoy Medical
―
Ownership Overview
11.73% Insiders
3.60% Mutual Funds
0.69% Other Institutional Investors
81.02% Public Companies and
Individual Investors